The European Commission has granted marketing authorization for Kostaive (ARCT-154), a self-amplifying mRNA COVID-19 vaccine, ...

A bill that would ban the use of mRNA vaccines, including for Covid-19, is on its way to the House floor after passing out of ...

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

Biotech firm Moderna reported a bigger-than-expected quarterly loss on Friday, hit by a charge related to its efforts to ...

Moderna (NASDAQ:MRNA) stock drops ~5% as its Q4 2024 results show revenue beat but earnings miss expectations. Read more here ...

Biotechnology company Moderna (NASDAQ:MRNA) in Q4 CY2024, but sales fell by 65.6% year on year to $966 million. On the other ...

They do not contain weakened or inactivated viruses. Instead, they do contain a type of genetic information (called mRNA) with instructions on how to create copies of the coronavirus’s ‘spike’ protein ...

The latest move is another step in the Trump administration’s campaign against Covid-19 vaccine requirements. Read more at ...

Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) and sa-mRNA pioneer Arcturus Therapeutics (Nasdaq: ARCT) today ...

Moderna is set to release its fourth-quarter earnings on Friday before the opening bell. Here's a look at what to expect in ...

COVID-19 vaccination is linked to a transient decrease in hyperthyroidism risk but an increase in hypothyroidism risk over 12 ...